Tevogen Inc. (TVGN)Healthcare | Biotechnology | Warren, United States | NasdaqGM
6.89 USD
+0.13
(1.923%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 6.81 -0.08 (-0.080%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:19 a.m. EDT
The immediate outlook is severely clouded by a massive 94% collapse in the trailing twelve-month performance, leaving the stock trading at a fraction of its historical value despite a recent technical bounce. While the latest year shows a recovery, the underlying business fundamentals are catastrophic, with negative book value, deep losses, and a balance sheet where debt nearly ten times exceeds cash reserves. The company is also diluting shareholders through equity plans and reverse splits, signaling distress rather than growth. With no dividend history and a statistical model predicting further downside, there is no rational case for a short-term trade or a long-term hold. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.491106 |
| AutoETS | 0.494876 |
| MSTL | 0.524560 |
| AutoTheta | 0.611208 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.052 |
| Excess Kurtosis | -0.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 44,864,508 |
| Beta | 0.20 |
| Previous Name | Semper Paratus Acquisition Corporation |
| Website | https://tevogen.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.84831464 |
| Address1 | 15 Independence Boulevard |
| Address2 | Suite #210 |
| All Time High | 1,054.5 |
| All Time Low | 3.636 |
| Ask | 8.3 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 6,080 |
| Average Daily Volume3 Month | 17,774 |
| Average Volume | 17,774 |
| Average Volume10Days | 6,080 |
| Beta | 0.199 |
| Bid | 4.83 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | -4.157 |
| City | Warren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.89 |
| Current Ratio | 0.327 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 6.89 |
| Day Low | 6.62 |
| Display Name | Tevogen |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -21,283,812 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.914 |
| Enterprise Value | 62,025,176 |
| Eps Trailing Twelve Months | -6.42 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.3476 |
| Fifty Day Average Change | 0.5423999 |
| Fifty Day Average Change Percent | 0.0854496 |
| Fifty Two Week Change Percent | -84.83147 |
| Fifty Two Week High | 49.5 |
| Fifty Two Week High Change | -42.61 |
| Fifty Two Week High Change Percent | -0.8608081 |
| Fifty Two Week Low | 3.636 |
| Fifty Two Week Low Change | 3.254 |
| Fifty Two Week Low Change Percent | 0.8949395 |
| Fifty Two Week Range | 3.636 - 49.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,641,393,000,000 |
| Float Shares | 1,938,095 |
| Free Cashflow | -3,051,937 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 18 |
| Fullday Change | 0.13 |
| Fullday Change Percent | 1.92307 |
| Fullday Price | 6.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.67160004 |
| Held Percent Institutions | 0.01657 |
| Implied Shares Outstanding | 6,511,540 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,772,755,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey. |
| Long Name | Tevogen Inc. |
| Market | us_market |
| Market Cap | 44,864,508 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_702249906 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -22,240,424 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 43,952,895 |
| Open | 6.62 |
| Operating Cashflow | -11,569,983 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 877 838 6436 |
| Post Market Change | -0.07999992 |
| Post Market Change Percent | -1.1611019 |
| Post Market Price | 6.81 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Semper Paratus Acquisition Corporation |
| Previous Close | 6.76 |
| Price Hint | 2 |
| Price To Book | -1.6574452 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.202 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.12999964 |
| Regular Market Change Percent | 1.9230714 |
| Regular Market Day High | 6.89 |
| Regular Market Day Low | 6.62 |
| Regular Market Day Range | 6.62 - 6.89 |
| Regular Market Open | 6.62 |
| Regular Market Previous Close | 6.76 |
| Regular Market Price | 6.89 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,598 |
| Return On Assets | -2.97366 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 6,511,540 |
| Shares Percent Shares Out | 0.009 |
| Shares Short | 58,741 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 64,847 |
| Short Name | Tevogen Inc. |
| Short Percent Of Float | 0.0153 |
| Short Ratio | 4.39 |
| Source Interval | 15 |
| State | NJ |
| Symbol | TVGN |
| Total Cash | 1,082,155 |
| Total Cash Per Share | 0.166 |
| Total Debt | 9,442,832 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.125675 |
| Two Hundred Day Average Change | -4.2356753 |
| Two Hundred Day Average Change Percent | -0.38071176 |
| Type Disp | Equity |
| Volume | 2,598 |
| Website | https://tevogen.com |
| Zip | 7,059 |